Biocryst Pharmaceuticals (BCRX) EBITDA Margin (2010 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly EBITDA Margin came in at 448.55% in Q1 2026, down 46314.0% YoY from N/an in Q1 2025, and down 101.22% on a QoQ basis from 36777.54% in Q4 2025.
Biocryst Pharmaceuticals (BCRX) EBITDA Margin (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 17 years of EBITDA Margin data on file, last reported at 448.55% in Q1 2026.
- Quarterly EBITDA Margin fell 46314.0% year-over-year to 448.55% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 79.57% (down 8616.0% YoY) and the FY2025 annual result came in at 38.98%, up 3954.0% from the prior year.
- EBITDA Margin slipped to 448.55% in Q1 2026, from 36777.54% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 36777.54% in Q4 2025 to a low of 448.55% in Q1 2026.
- A 5-year average of 2118.58% and a median of 15.62% in 2024 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2025 — EBITDA Margin soared 3678097 bps — and 2026, when it sank 46314 bps.
- Tracing BCRX's EBITDA Margin over 5 years: stood at 58.22% in 2022, then climbed by 22 bps to 45.68% in 2023, then soared by 92 bps to 3.43% in 2024, then jumped by 1073192 bps to 36777.54% in 2025, then tumbled by 101 bps to 448.55% in 2026.
- The last three EBITDA Margin figures came in at 448.55% (Q1 2026), 36777.54% (Q4 2025), and 18.56% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -5.58% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 33.91% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 16.51% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 42.23% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 0.17% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 15.80% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 18.13% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.11 Bn | 214.41 Mn | 45.12% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 45.12% |
| Mar 31, 2026 | -448.55% |
| Dec 31, 2025 | 36,777.54% |
| Sep 30, 2025 | 18.56% |
| Jun 30, 2025 | 18.23% |
| Mar 31, 2025 | 14.59% |
| Dec 31, 2024 | -3.43% |
| Sep 30, 2024 | 6.57% |
| Jun 30, 2024 | 8.01% |
| Mar 31, 2024 | -15.62% |
| Dec 31, 2023 | -45.68% |
| Sep 30, 2023 | -13.74% |
| Jun 30, 2023 | -25.10% |
| Mar 31, 2023 | -41.31% |
| Dec 31, 2022 | -58.22% |
| Sep 30, 2022 | -23.01% |
| Jun 30, 2022 | -52.98% |
| Mar 31, 2022 | -100.07% |
| Dec 31, 2021 | -110.64% |
| Sep 30, 2021 | -108.76% |